SULANEMADLIN
TP53 wt Allele
M.D. Anderson Cancer Centerprotein_peptidePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 31/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the TP53 wt Allele cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Osimertinib Jonsson Comprehensive Cancer Center | Phase 2 | B |
FLUDEOXYGLUCOSE Jonsson Comprehensive Cancer Center | Phase 2 | B |
Ribociclib St. Jude Children's Research Hospital | Phase 1 | CC |
gsk1120212 St. Jude Children's Research Hospital | Phase 1 | CC |
Sonidegib St. Jude Children's Research Hospital | Phase 1 | CC |
FILGRASTIM St. Jude Children's Research Hospital | Phase 1 | CC |
Same molecule, other indications
SULANEMADLIN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →